Novocure's Premarket Application for Brain Metastases Treatment Otpune Mya Rejected by FDA
By Robb M. Stewart
Novocure's application for U.S. premarket approval for a treatment for brain metastases has been knocked back by the Food and Drug Administration.
The Swiss company said Monday it received a "not approvable" letter from the FDA in response to its application for Optune Mya for the treatment of adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation.
The letter indicated the regulator determined that uncertainty around the degree of clinical benefit provided by Optune Mya prevented approval of the premarket application, Novocure said. The company said the FDA didn't raise concerns related to the safety profile of Optune Mya.
Novocure's shares retreated in premarket trading, falling 2.4% to $12.96 on Nasdaq. As of Friday's close, the stock was down 19% over the last three months to narrow the year-to-date advance to 2.7%.
The oncology company said it is evaluating the feedback and plans to meet with the FDA to determine if there are any options that would support approval of its application that wouldn't require additional clinical studies. There can be no assurance that these discussions or any future submissions regarding this premarket approval application will lead to an approval, it said.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
November 09, 2026 08:01 ET (13:01 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?

